Replies to post #345408 on Amarin Corp Plc (AMRN)

[Monk44]

There you go LM, from the expert, PDude.

[sstyles]

Could be a market in the USA for the anti-vaxers.

Will be interesting to see if the stock price reacts to the August presentation / late-breaker.

[Laurent Maldague]

Thanks, I suspect the same regarding patents based on CardioLink-9. The distinct dosing regime is also a very good point.

With regards to ECLA and KP, I've done some searching on IP and investigator-initiated trials. Seems like it's standard for the PI's institution to sell off (assign) or exclusively license any patents generated from such trials.

https://dsp.research.uiowa.edu/investigator-initiated-clinical-trials

https://clinicaltrials.usc.edu/intellectual-property-terms-in-research-agreements/

Perhaps the end result will be something similar to CVD patents (a mixture of licensed patents from Mochida + in-house IP from Reduce IT.)

I agree the generics are going to sell with disregard for their approved indication, but the smaller their piece of the pie (legally speaking), the better for our infringement case.

[ralphey]

PD .... based on what you say if AMRN just revised their name to VAscepa-CAD meaning vascepa for CAD - this would prevent all CAD infringement ?